Author:
Dubey Divyanshu,Sguigna Peter,Stüve Olaf
Publisher
Springer Science and Business Media LLC
Reference71 articles.
1. Montalban X, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study. http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/116701/xavier.montalban.efficacy.and.safety.of.ocrelizumab.in.primary.progressive.html?f=m3 . Accessed 13 Apr 2016.
2. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One. 2013;8:e66308.
3. Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 2015;14:194–207.
4. Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler. 2001;7:354–8.
5. Schmidt S. Fampridine improves severe dysarthria in secondary-progressive multiple sclerosis. Mult Scler. 2013;19:511.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献